{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:38:47Z","timestamp":1790696327614,"version":"4.1.0"},"reference-count":213,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2019,4,1]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Application of coordination chemistry in nanotechnology is a rapidly developing research field in medicine. Bismuth complexes have been widely used in biomedicine with satisfactory therapeutic effects, mostly in Helicobacter pylori eradication, but also as potential antimicrobial and anti-leishmanial agents. Additionally, in recent years, application of bismuth-based compounds as potent anticancer drugs has been studied extensively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Search for data connected with recent trends on bismuth compounds in cancer chemo- and radiotherapy was carried out using web-based literature searching tools such as ScienceDirect, Springer, Royal Society of Chemistry, American Chemical Society and Wiley. Pertinent literature is covered up to 2016.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>In this review, based on 213 papers, we highlighted a number of current problems connected with: (i) characterization of bismuth complexes with selected thiosemicarbazone, hydrazone, and dithiocarbamate classes of ligands as potential chemotherapeutics. Literature results derived from 50 papers show that almost all bismuth compounds inhibit growth and proliferation of breast, colon, ovarian, lung, and other tumours; (ii) pioneering research on application of bismuth-based nanoparticles and nanodots for radiosensitization. Results show great promise for improvement in therapeutic efficacy of ionizing radiation in advanced radiotherapy (described in 36 papers); and (iii) research challenges in using bismuth radionuclides in targeted radioimmunotherapy, connected with choice of adequate radionuclide, targeting vector, proper bifunctional ligand and problems with 213Bi recoil daughters toxicity (derived from 92 papers).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>This review presents recent research trends on bismuth compounds in cancer chemo- and radiotherapy, suggesting directions for future research.<\/jats:p><\/jats:sec>","DOI":"10.2174\/0929867324666171003113540","type":"journal-article","created":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T09:58:43Z","timestamp":1507111123000},"page":"729-759","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Recent Research Trends on Bismuth Compounds in Cancer Chemoand Radiotherapy"],"prefix":"10.2174","volume":"26","author":[{"given":"Mateusz","family":"Kowalik","sequence":"first","affiliation":[{"name":"Institute of Chemistry, Jan Kochanowski University in Kielce, Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Masternak","sequence":"additional","affiliation":[{"name":"Institute of Chemistry, Jan Kochanowski University in Kielce, Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Barszcz","sequence":"additional","affiliation":[{"name":"Institute of Chemistry, Jan Kochanowski University in Kielce, Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1351\/pac199870040863","volume":"70","author":"Sadler P.J.","year":"1998","unstructured":"Sadler PJ, Guo Z. Metal complexes in medicine: Design and mechanism of action.","journal-title":"Pure Appl Chem"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0010-8545(98)90033-9","volume":"171","author":"Stochel G.","year":"1998","unstructured":"Stochel G, Wanat A, Kuli\u015b E, Stasicka Z. Light and metal complexes in medicine.","journal-title":"Coord Chem Rev"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1367-5931(03)00081-4","volume":"7","author":"Zhang C.X.","year":"2003","unstructured":"Zhang CX, Lippard SJ. New metal complexes as potential therapeutics.","journal-title":"Curr Opin Chem Biol"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1039\/B513476E","volume":"6","author":"Thompson K.H.","year":"2006","unstructured":"Thompson KH, Orvig C. Metal complexes in medicinal chemistry: new vistas and challenges in drug design.","journal-title":"Dalton Trans"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cbpa.2007.11.013","volume":"12","author":"Bruijnincx P.C.","year":"2008","unstructured":"Bruijnincx PC, Sadler PJ. New trends for metal complexes with anticancer activity.","journal-title":"Curr Opin Chem Biol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cbpa.2012.01.013","volume":"16","author":"Gasser G.","year":"2012","unstructured":"Gasser G, Metzler-Nolte N. The potential of organometallic complexes in medicinal chemistry.","journal-title":"Curr Opin Chem Biol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cbpa.2014.02.003","volume":"19","author":"Muhammad N.","year":"2014","unstructured":"Muhammad N, Guo Z. Metal-based anticancer chemotherapeutic agents.","journal-title":"Curr Opin Chem Biol"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1021\/cr400460s","volume":"114","author":"Mjos K.D.","year":"2014","unstructured":"Mjos KD, Orvig C. Metallodrugs in medicinal inorganic chemistry.","journal-title":"Chem Rev"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1021\/nn403220e","volume":"7","author":"Barry N.P.E.","year":"2013","unstructured":"Barry NPE, Sadler PJ. Challenges for metals in medicine\u202f: To shape the future.","journal-title":"ACS Nano"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0010-8545(97)00042-8","volume":"163","author":"Dittes U.","year":"1997","unstructured":"Dittes U, Vogel E, Keppler BK. Overview on bismuth(III) and bismuth(V) complexes with activity against Helicobacter pylori.","journal-title":"Coord Chem Rev"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0010-8545(99)00018-1","volume":"185-186","author":"Sadler P.J.","year":"1999","unstructured":"Sadler PJ, Li H, Sun H. Coordination chemistry of metals in medicine: Target sites for bismuth.","journal-title":"Coord Chem Rev"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1016\/j.ccr.2007.03.003","volume":"251","author":"Yang N.","year":"2007","unstructured":"Yang N, Sun H. Biocoordination chemistry of bismuth: Recent advances.","journal-title":"Coord Chem Rev"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cbpa.2012.01.006","volume":"16","author":"Li H.","year":"2012","unstructured":"Li H, Sun H. Recent advances in bioinorganic chemistry of bismuth.","journal-title":"Curr Opin Chem Biol"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ccr.2011.06.014","volume":"256","author":"Witkowska D.","year":"2012","unstructured":"Witkowska D, Rowinska-\u017byrek M, Valensin G, Kozlowski H. Specific poly-histidyl and poly-cysteil protein sites involved in Ni2+ homeostasis in Helicobacter pylori. Impact of Bi3+ ions on Ni2+ binding to proteins. Structural and thermodynamic aspects.","journal-title":"Coord Chem Rev"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"15258","DOI":"10.3390\/molecules190915258","volume":"19","author":"Keogan D.M.","year":"2014","unstructured":"Keogan DM, Griffith DM. Current and potential applications of bismuth-based drugs.","journal-title":"Molecules"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jconrel.2014.06.020","volume":"189","author":"Lopes D.","year":"2014","unstructured":"Lopes D, Nunes C, Martins MCL, Sarmento B, Reis S. Eradication of Helicobacter pylori: Past, present and future.","journal-title":"J Control Release"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/00958972.2014.999672","volume":"68","author":"Yang Y.","year":"2015","unstructured":"Yang Y, Ouyang R, Xu L, Guo N, Li W, Feng K, Ouyang L, Yang Z, Zhou S, Miao Y. Review: Bismuth complexes: Synthesis and applications in biomedicine.","journal-title":"J Coord Chem"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/apt.13128","volume":"41","author":"Gisbert J.P.","year":"2015","unstructured":"Gisbert JP, Romano M, Gravina AG, Sol\u00eds-Mu\u00f1oz P, Bermejo F, Molina-Infante J, Castro-Fern\u00e1ndez M, Ortu\u00f1o J, Lucendo AJ, Herranz M, Modolell I, Del Castillo F, G\u00f3mez J, Barrio J, Velayos B, G\u00f3mez B, Dom\u00ednguez JL, Miranda A, Martorano M, Algaba A, Pab\u00f3n M, Angueira T, Fern\u00e1ndez-Salazar L, Federico A, Mar\u00edn AC, McNicholl AG. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1002\/cbdv.201100447","volume":"9","author":"Lessa J.A.","year":"2012","unstructured":"Lessa JA, Reis DC, Da Silva JG, Paradizzi LT, da Silva NF. Carvalho, Mde.F.; Siqueira, S.A.; Beraldo, H. Coordination of thiosemicarbazones and bis(thiosemicarbazones) to bismuth(III) as a strategy for the design of metal-based antibacterial agents.","journal-title":"Chem Biodivers"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ejic.201402958","author":"Luqman A.","year":"2015","unstructured":"Luqman A, Blair VL, Brammananth R, Crellin PK, Coppel RL, Kedzierski L, Andrews PC. Homoleptic and heteroleptic bismuth(III) thiazole-thiolates and the influence of ring substitution on their antibacterial and antileishmanial activity.","journal-title":"Eur J Inorg Chem"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jinorgbio.2010.08.007","volume":"105","author":"Andrews P.C.","year":"2011","unstructured":"Andrews PC, Frank R, Junk PC, Kedzierski L, Kumar I, MacLellan JG. Anti-Leishmanial activity of homo- and heteroleptic bismuth(III) carboxylates.","journal-title":"J Inorg Biochem"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"18215","DOI":"10.1039\/C5DT03335G","volume":"44","author":"Ong Y.C.","year":"2015","unstructured":"Ong YC, Blair VL, Kedzierski L, Tuck KL, Andrews PC. Stability and toxicity of tris-tolyl bismuth(V) dicarboxylates and their biological activity towards Leishmania major.","journal-title":"Dalton Trans"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"12904","DOI":"10.1039\/C4DT00957F","volume":"43","author":"Ong Y.C.","year":"2014","unstructured":"Ong YC, Blair VL, Kedzierski L, Andrews PC. Stability and toxicity of heteroleptic organometallic Bi(V) complexes towards Leishmania major.","journal-title":"Dalton Trans"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0010-8545(00)00363-5","volume":"209","author":"Casas J.S.","year":"2000","unstructured":"Casas JS, Garc\u00eda-Tasende MS, Sordo J. Main group metal complexes of semicarbazones and thiosemicarbazones. A structural review.","journal-title":"Coord Chem Rev"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.ccr.2008.07.004","volume":"253","author":"Lobana T.S.","year":"2009","unstructured":"Lobana TS, Sharma R, Bawa G, Khanna S. Bonding and structure trends of thiosemicarbazone derivatives of metals-An overview.","journal-title":"Coord Chem Rev"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2174\/1874846501003020016","volume":"3","author":"Pelosi G.","year":"2010","unstructured":"Pelosi G. Thiosemicarbazone metal complexes: From structure to activity.","journal-title":"Open Crystallogr J"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cct.2003.11.004","volume":"248","author":"Quiroga A.G.","year":"2004","unstructured":"Quiroga AG, Ranninger CN. Contribution to the SAR field of metallated and coordination complexes: Studies of the palladium and platinum derivatives with selected thiosemicarbazones as antitumoral drugs.","journal-title":"Coord Chem Rev"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1021\/jm900552r","volume":"52","author":"Yu Y.","year":"2009","unstructured":"Yu Y, Kalinowski DS, Kovacevic Z, Siafakas AR, Jansson PJ, Stefani C, Lovejoy DB, Sharpe PC, Bernhardt PV, Richardson DR. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.","journal-title":"J Med Chem"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/1389557043487484","volume":"4","author":"Beraldo H.","year":"2004","unstructured":"Beraldo H, Gambino D. The wide pharmacological versatility of semicarbazones, thiosemicarba-zones and their metal complexes.","journal-title":"Mini Rev Med Chem"},{"key":"ref=30","first-page":"193","volume":"23","author":"Ali R.","year":"2012","unstructured":"Ali R, Marella A, Alam T, Naz R. Review of biological activities of hydrazones.","journal-title":"Indones J Pharm"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3998\/ark.5550190.0011.108","volume":"2010","author":"Belskaya N.P.","year":"2010","unstructured":"Belskaya NP, Dehaen W, Bakuleva VA. Synthesis and properties of hydrazones bearing amide, thioamide and amidine functions.","journal-title":"ARKIVOC"},{"key":"ref=32","first-page":"761030","volume":"2014","author":"Kajal A.","year":"2014","unstructured":"Kajal A, Bala S, Sharma N, Kamboj S, Saini V. Therapeutic potential of hydrazones as anti-inflammatory agents.","journal-title":"Int J Med Chem"},{"key":"ref=33","first-page":"100","volume":"2","author":"Negi V.J.","year":"2012","unstructured":"Negi VJ, Sharma AK, Negi JS, Ram V. Biological activities of hydrazone derivatives in the new millenium.","journal-title":"Int J Pharm Chrm"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.arabjc.2013.04.026","volume":"7","author":"Kanchi S.","year":"2014","unstructured":"Kanchi S, Singh P, Bisetty K. Dithiocarbamates as hazardous remediation agent: A critical review on progress in environmental chemistry for inorganic species studies of 20th century.","journal-title":"Arab J Chem"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/aoc.1441","volume":"22","author":"Tiekink E.R.T.","year":"2008","unstructured":"Tiekink ERT. Tin dithiocarbamates: Applications and structures.","journal-title":"Appl Organomet Chem"},{"key":"ref=36","first-page":"167","volume":"16","author":"Brockman R.W.","year":"1956","unstructured":"Brockman RW, Thomson JR, Bell MJ, Skipper HE. Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone.","journal-title":"Cancer Res"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0065-2571(98)00017-X","volume":"39","author":"Finch R.A.","year":"1999","unstructured":"Finch RA, Liu M-C, Cory AH, Cory JG, Sartorelli AC. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity.","journal-title":"Adv Enzyme Regul"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1158\/1078-0432.CCR-06-1954","volume":"12","author":"Yu Y.","year":"2006","unstructured":"Yu Y, Wong J, Lovejoy DB, Kalinowski DS, Richardson DR. Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.","journal-title":"Clin Cancer Res"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10637-007-9085-0","volume":"26","author":"Ma B.","year":"2008","unstructured":"Ma B, Goh BC, Tan EH, Lam KC, Soo R, Leong SS, Wang LZ, Mo F, Chan ATC, Zee B, Mok T. A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells.","journal-title":"Invest New Drugs"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10637-007-9066-3","volume":"25","author":"Mackenzie M.J.","year":"2007","unstructured":"Mackenzie MJ, Saltman D, Hirte H, Low J, Johnson C, Pond G, Moore MJ. A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium.","journal-title":"Invest New Drugs"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10637-007-9044-9","volume":"25","author":"Knox J.J.","year":"2007","unstructured":"Knox JJ, Hotte SJ, Kollmannsberger C, Winquist E, Fisher B, Eisenhauer EA. Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161).","journal-title":"Invest New Drugs"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.inoche.2012.02.009","volume":"20","author":"Zhang L-Z.","year":"2012","unstructured":"Zhang L-Z, An G-Y, Yang M, Li M-X, Zhu X-F. Synthesis, characterization, crystal structure and biological activities of the unusual main group 8-coordinate bismuth(III) complex derived from 2-acetylpyrazine N4-pyridylthiosemicarbazone.","journal-title":"Inorg Chem Commun"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ejmech.2014.07.055","volume":"84","author":"Parrilha G.L.","year":"2014","unstructured":"Parrilha GL, Ferraz KSO, Lessa JA, de Oliveira KN, Rodrigues BL, Ramos JP, Souza-Fagundes EM, Ott I, Beraldo H. Metal complexes with 2-acetylpyridine-N(4)-orthochlorophenylthiosemicarbazone: cytotoxicity and effect on the enzymatic activity of thioredoxin reductase and glutathione reductase.","journal-title":"Eur J Med Chem"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"12521","DOI":"10.1021\/ic301959z","volume":"51","author":"Li M-X.","year":"2012","unstructured":"Li M-X, Yang M, Niu JY, Zhang L-Z, Xie S-Q. A nine-coordinated bismuth(III) complex derived from pentadentate 2,6-diacetylpyridine bis((4)N-methylthiosemicarbazone): crystal structure and both in vitro and in vivo biological evaluation.","journal-title":"Inorg Chem"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"12882","DOI":"10.1039\/c2dt31256e","volume":"41","author":"Li M.","year":"2012","unstructured":"Li M, Lu Y, Yang M, Li Y, Zhang L, Xie S. One dodecahedral bismuth(III) complex derived from 2-acetylpyridine N(4)-pyridylthiosemicarbazone: synthesis, crystal structure and biological evaluation.","journal-title":"Dalton Trans"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.bmcl.2012.02.024","volume":"22","author":"Li M-X.","year":"2012","unstructured":"Li M-X, Zhang LZ, Yang M, Niu JY, Zhou J. Synthesis, crystal structures, in vitro biological evaluation of zinc(II) and bismuth(III) complexes of 2-acetylpyrazine N(4)-phenylthiosemicarbazone.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.bmcl.2013.02.097","volume":"23","author":"Li Y-K.","year":"2013","unstructured":"Li Y-K, Yang M, Li M-X, Yu H, Wu H-C, Xie S-Q. Synthesis, crystal structure and biological evaluation of a main group seven-coordinated bismuth(III) complex with 2-acetylpyridine N4-phenylthiosemicarbazone.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.3390\/12081910","volume":"12","author":"Rollas S.","year":"2007","unstructured":"Rollas S, K\u00fc\u00e7\u00fckg\u00fczel \u015eG. Biological activities of hydrazone derivatives.","journal-title":"Molecules"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1021\/ic00028a014","volume":"31","author":"Cornelissen J.P.","year":"1992","unstructured":"Cornelissen JP, van Diemen JH, Groeneveld LR, Haasnoot JG, Spek AL, Reedijk J. Synthesis and properties of isostructural transition-metal (copper, nickel, cobalt, and iron) compounds with 7,7\u2032,8,8\u2032-tetracyanoquinodimethanide(1-) in an unusual monodentate coordination mode: Crystal structure of bis(3,5-bis(pyridin-2-yl)-4-amino-1,2,4-triazole)bis(7,7\u2032,8,8\u2032-tetracyanoquinodimethanido)-copper(II).","journal-title":"Inorg Chem"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"17202","DOI":"10.3390\/molecules191117202","volume":"19","author":"Recio Despaigne A.A.","year":"2014","unstructured":"Recio Despaigne AA, Da Silva JG, da Costa PR, Dos Santos RG, Beraldo H. ROS-mediated cytotoxic effect of copper(II) hydrazone complexes against human glioma cells.","journal-title":"Molecules"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejmech.2012.01.051","volume":"50","author":"Despaigne A.A.R.","year":"2012","unstructured":"Despaigne AAR, Parrilha GL, Izidoro JB, da Costa PR, dos Santos RG, Piro OE, Castellano EE, Rocha WR, Beraldo H. 2-Acetylpyridine- and 2-benzoylpyridine-derived hydrazones and their gallium(III) complexes are highly cytotoxic to glioma cells.","journal-title":"Eur J Med Chem"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/S0968-0896(01)00133-X","volume":"9","author":"Bottari B.","year":"2001","unstructured":"Bottari B, Maccari R, Monforte F, Ottan\u00e0 R, Vigorita MG, Bruno G, Nicol\u00f2 F, Rotondo A, Rotondo E. Nickel(II) 2,6-diacetylpyridine bis(isonicotinoylhydrazonate) and bis(benzoylhydrazonate) complexes: structure and antimycobacterial evaluation. Part XI.","journal-title":"Bioorg Med Chem"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1016\/j.bmc.2016.05.007","volume":"24","author":"Ferreira I.P.","year":"2016","unstructured":"Ferreira IP, Pil\u00f3 EDL, Recio-Despaigne AA, Da Silva JG, Ramos JP, Marques LB, Prazeres PHDM, Takahashi JA, Souza-Fagundes EM, Rocha W, Beraldo H. Bismuth(III) complexes with 2-acetylpyridine- and 2-benzoylpyridine-derived hydrazones: Antimicrobial and cytotoxic activities and effects on the clonogenic survival of human solid tumor cells.","journal-title":"Bioorg Med Chem"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejmech.2012.03.040","volume":"53","author":"Ferraz K.S.O.","year":"2012","unstructured":"Ferraz KSO, Silva NF, da Silva JG, de Miranda LF, Romeiro CFD, Souza-Fagundes EM, Mendes IC, Beraldo H. Investigation on the pharmacological profile of 2,6-diacetylpyridine bis(benzoylhydrazone) derivatives and their antimony(III) and bismuth(III) complexes.","journal-title":"Eur J Med Chem"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1039\/c4dt00077c","volume":"43","author":"Zhang N.","year":"2014","unstructured":"Zhang N, Tai Y, Li M, Ma P, Zhao J, Niu J. Main group bismuth(III), gallium(III) and diorganotin(IV) complexes derived from bis(2-acetylpyrazine)thiocarbonohydrazone: synthesis, crystal structures and biological evaluation.","journal-title":"Dalton Trans"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1021\/ic800404e","volume":"47","author":"Giovagnini L.","year":"2008","unstructured":"Giovagnini L, Sitran S, Montopoli M, Caparrotta L, Corsini M, Rosani C, Zanello P, Dou QP, Fregona D. Chemical and biological profiles of novel copper(II) complexes containing S-donor ligands for the treatment of cancer.","journal-title":"Inorg Chem"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1021\/cr400135x","volume":"114","author":"Santini C.","year":"2014","unstructured":"Santini C, Pellei M, Gandin V, Porchia M, Tisato F, Marzano C. Advances in copper complexes as anticancer agents.","journal-title":"Chem Rev"},{"key":"ref=58","first-page":"1","volume":"73","author":"Castegnaro M.","year":"1985","unstructured":"Castegnaro M. Laboratory decontamination and destruction of carcinogens in laboratory wastes: some antineoplastic agents.","journal-title":"IARC Sci Publ"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.poly.2013.08.052","volume":"67","author":"Ozturk I.I.","year":"2014","unstructured":"Ozturk II, Banti CN, Kourkoumelis N, Manos MJ, Tasiopoulos AJ, Owczarzak AM, Kubicki M, Hadjikakou SK. Synthesis, characterization and biological activity of antimony(III) or bismuth(III) chloride complexes with dithiocarbamate ligands derived from thiuram degradation.","journal-title":"Polyhedron"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jinorgbio.2007.01.010","volume":"101","author":"Li H.","year":"2007","unstructured":"Li H, Lai CS, Wu J, Ho PC, de Vos D, Tiekink ERT. Cytotoxicity, qualitative structure-activity relationship (QSAR), and anti-tumor activity of bismuth dithiocarbamate complexes.","journal-title":"J Inorg Biochem"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1021\/ic048260v","volume":"44","author":"Ronconi L.","year":"2005","unstructured":"Ronconi L, Giovagnini L, Marzano C, Bett\u00eco F, Graziani R, Pilloni G, Fregona D. Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in vitro antitumor activity.","journal-title":"Inorg Chem"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1021\/jm0508888","volume":"49","author":"Gaspari P.","year":"2006","unstructured":"Gaspari P, Banerjee T, Malachowski WP, Muller AJ, Prendergast GC, Du Hadaway J, Bennett S, Donovan AM. Structure-activity study of brassinin derivatives asindoleamine 2,3-dioxygenase inhibitors.","journal-title":"J Med Chem"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/0360-3016(84)90506-6","volume":"10","author":"Wagner H.","year":"1984","unstructured":"Wagner H, Parkinson DR, Madoc-Jones H, Sternick ES, Vrusho K, Krasin F. Combined effect of diethyldithiocarbamate (DDC) and modest hyperthermia on Chinese hamster (V79) cell survival and DNA strand break repair following photon irradiation.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1021\/cr00097a005","volume":"89","author":"Finet J.P.","year":"1989","unstructured":"Finet JP. Arylation reactions with organobismuth reagents.","journal-title":"Chem Rev"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/cr60096a008","volume":"30","author":"Gilman H.","year":"1942","unstructured":"Gilman H, Yale HL. Organobismuth compounds.","journal-title":"Chem Rev"},{"key":"ref=66","first-page":"1634","volume":"18","author":"Jiang Q.Y.","year":"2006","unstructured":"Jiang QY, Shen J, Zhong GQ. Synthesis of bismuth(III) complexes and coordination chemistry of bismuth(III).","journal-title":"Huaxue Jinzhan"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1055\/s-1997-1194","author":"Suzuki H.","year":"1997","unstructured":"Suzuki H, Ikegami T, Matano Y. Bismuth in organic transformations.","journal-title":"Synthesis"},{"key":"ref=68","first-page":"878","volume":"20","author":"Zhang X.W.","year":"2008","unstructured":"Zhang XW, Yin SF, Wu SS, Dai WL, Li WS, Zhou XP. Organobismuth chemistry in the past decade.","journal-title":"Huaxue Jinzhan"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.3390\/molecules16054191","volume":"16","author":"Luan J.","year":"2011","unstructured":"Luan J, Zhang L, Hu Z. Synthesis, properties characterization and applications of various organobismuth compounds.","journal-title":"Molecules"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S1040-8428(01)00217-7","volume":"42","author":"Tiekink E.R.T.","year":"2002","unstructured":"Tiekink ERT. Antimony and bismuth compounds in oncology.","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1155\/MBD.1998.295","volume":"5","author":"Smith K.A.","year":"1998","unstructured":"Smith KA, Deacon GB, Jackson WR, Tiekink ERT, Rainone S, Webster LK. Preapartion and anti-tumour activity of some arylbismuth(III) oxine complexes.","journal-title":"Met Based Drugs"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1016\/j.jorganchem.2009.05.003","volume":"694","author":"Zhang X.W.","year":"2009","unstructured":"Zhang XW, Xia J, Yan HW, Luo SL, Yin SF, Au CT, Wong WY. Synthesis, structure, and in vitro antiproliferative activity of cyclic hypervalent organobismuth(III) chlorides and their triphenylgermylpropionate derivatives.","journal-title":"J Organomet Chem"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.3390\/molecules18021464","volume":"18","author":"Marzano I.M.","year":"2013","unstructured":"Marzano IM, Franco MS, Silva PP, Augusti R, Santos GC, Fernandes NG, Bucciarelli-Rodriguez M, Chartone-Souza E, Pereira-Maia EC. Crystal structure, antibacterial and cytotoxic activities of a new complex of bismuth(III) with sulfapyridine.","journal-title":"Molecules"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.poly.2013.07.008","volume":"63","author":"Ferraz K.S.O.","year":"2013","unstructured":"Ferraz KSO, Reis DC, Da Silva JG, Souza-Fagundes EM, Baran EJ, Beraldo H. Investigation on the bioactivities of clioquinol and its bismuth(III) and platinum(II, IV) complexes.","journal-title":"Polyhedron"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"12184","DOI":"10.1021\/ic400226g","volume":"52","author":"Preihs C.","year":"2013","unstructured":"Preihs C, Arambula JF, Magda D, Jeong H, Yoo D, Cheon J, Siddik ZH, Sessler JL. Recent developments in texaphyrin chemistry and drug discovery.","journal-title":"Inorg Chem"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"7900","DOI":"10.1039\/c0cc03528a","volume":"46","author":"Preihs C.","year":"2010","unstructured":"Preihs C, Arambula JF, Lynch VM, Siddik ZH, Sessler JL. Bismuth- and lead-texaphyrin complexes: towards potential \u03b1-core emitters for radiotherapy.","journal-title":"Chem Commun (Camb)"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxlet.2008.08.015","volume":"182","author":"Mao X.","year":"2008","unstructured":"Mao X, Schimmer AD. The toxicology of Clioquinol.","journal-title":"Toxicol Lett"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1016\/j.ejmech.2010.03.008","volume":"45","author":"Shaw A.Y.","year":"2010","unstructured":"Shaw AY, Chang C-Y, Hsu M-Y, Lu P-J, Yang C-N, Chen H-L, Lo C-W, Shiau C-W, Chern M-K. Synthesis and structure-activity relationship study of 8-hydroxyquinoline-derived Mannich bases as anticancer agents.","journal-title":"Eur J Med Chem"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1158\/1535-7163.MCT-06-0067","volume":"5","author":"Ding W-Q.","year":"2006","unstructured":"Ding W-Q, Liu B, Vaught JL, Palmiter RD, Lind SE. Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells.","journal-title":"Mol Cancer Ther"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1158\/0008-5472.CAN-04-3577","volume":"65","author":"Ding W.Q.","year":"2005","unstructured":"Ding WQ, Liu B, Vaught JL, Yamauchi H, Lind SE. Anticancer activity of the antibiotic clioquinol.","journal-title":"Cancer Res"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1016\/j.ejmech.2009.05.017","volume":"44","author":"Ghorab M.M.","year":"2009","unstructured":"Ghorab MM, Ragab FA, Hamed MM. Design, synthesis and anticancer evaluation of novel tetrahydroquinoline derivatives containing sulfonamide moiety.","journal-title":"Eur J Med Chem"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/jhet.1047","volume":"49","author":"Li Z.","year":"2012","unstructured":"Li Z, Zhu A, Yang J. One-pot three-component mild synthesis of 2-aryl-3-(9-alkylcarbazol-3-yl)thiazolin-4-ones.","journal-title":"J Heterocycl Chem"},{"key":"ref=83","first-page":"133","volume":"4","author":"Avenda\u00f1o C.","year":"2015","unstructured":"Avenda\u00f1o C, Men\u00e9ndez JC. Anticancer Drugs Acting via Radical SpeciesMedicinal Chemistry of Anticancer Drugs,"},{"key":"ref=84","author":"Hall E. J.","year":"2000","unstructured":"Hall E J.","journal-title":"Radiobiology for The Radiologist"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1667\/RR1984.1","volume":"173","author":"Chithrani D.B.","year":"2010","unstructured":"Chithrani DB, Jelveh S, Jalali F, van Prooijen M, Allen C, Bristow RG, Hill RP, Jaffray DA. Gold nanoparticles as radiation sensitizers in cancer therapy.","journal-title":"Radiat Res"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.rpor.2010.09.001","volume":"15","author":"Mesbahi A.","year":"2010","unstructured":"Mesbahi A. A review on gold nanoparticles radiosensitization effect in radiation therapy of cancer.","journal-title":"Rep Pract Oncol Radiother"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1088\/0031-9155\/55\/11\/004","volume":"55","author":"Hainfeld J.F.","year":"2010","unstructured":"Hainfeld JF, Dilmanian FA, Zhong Z, Slatkin DN, Kalef-Ezra JA, Smilowitz HM. Gold nanoparticles enhance the radiation therapy of a murine squamous cell carcinoma.","journal-title":"Phys Med Biol"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nano.2009.01.014","volume":"5","author":"Rahman W.N.","year":"2009","unstructured":"Rahman WN, Bishara N, Ackerly T, He CF, Jackson P, Wong C, Davidson R, Geso M. Enhancement of radiation effects by gold nanoparticles for superficial radiation therapy.","journal-title":"Nanomedicine (Lond)"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1211\/jpp.60.8.0005","volume":"60","author":"Hainfeld J.F.","year":"2008","unstructured":"Hainfeld JF, Dilmanian FA, Slatkin DN, Smilowitz HM. Radiotherapy enhancement with gold nanoparticles.","journal-title":"J Pharm Pharmacol"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"375101","DOI":"10.1088\/0957-4484\/20\/37\/375101","volume":"20","author":"Roa W.","year":"2009","unstructured":"Roa W, Zhang X, Guo L, Shaw A, Hu X, Xiong Y, Gulavita S, Patel S, Sun X, Chen J, Moore R, Xing JZ. Gold nanoparticle sensitize radiotherapy of prostate cancer cells by regulation of the cell cycle.","journal-title":"Nanotechnology"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"193702","DOI":"10.1063\/1.3589914","volume":"98","author":"Polf J.C.","year":"2011","unstructured":"Polf JC, Bronk LF, Driessen WHP, Arap W, Pasqualini R, Gillin M. Enhanced relative biological effectiveness of proton radiotherapy in tumor cells with internalized gold nanoparticles.","journal-title":"Appl Phys Lett"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijrobp.2010.10.022","volume":"81","author":"Berbeco R.I.","year":"2011","unstructured":"Berbeco RI, Ngwa W, Makrigiorgos GM. Localized dose enhancement to tumor blood vessel endothelial cells via megavoltage X-rays and targeted gold nanoparticles: new potential for external beam radiotherapy.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"6533","DOI":"10.1088\/0031-9155\/55\/21\/013","volume":"55","author":"Ngwa W.","year":"2010","unstructured":"Ngwa W, Makrigiorgos GM, Berbeco RI. Applying gold nanoparticles as tumor-vascular disrupting agents during brachytherapy: estimation of endothelial dose enhancement.","journal-title":"Phys Med Biol"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1118\/1.3671905","volume":"39","author":"Ngwa W.","year":"2012","unstructured":"Ngwa W, Makrigiorgos GM, Berbeco RI. Gold nanoparticle-aided brachytherapy with vascular dose painting: estimation of dose enhancement to the tumor endothelial cell nucleus.","journal-title":"Med Phys"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1021\/ja9102698","volume":"132","author":"Kang B.","year":"2010","unstructured":"Kang B, Mackey MA, El-Sayed MA. Nuclear targeting of gold nanoparticles in cancer cells induces DNA damage, causing cytokinesis arrest and apoptosis.","journal-title":"J Am Chem Soc"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/wnan.1322","volume":"7","author":"Yamada M.","year":"2015","unstructured":"Yamada M, Foote M, Prow TW. Therapeutic gold, silver, and platinum nanoparticles.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1039\/c2nr31227a","volume":"4","author":"Butterworth K.T.","year":"2012","unstructured":"Butterworth KT, McMahon SJ, Currell FJ, Prise KM. Physical basis and biological mechanisms of gold nanoparticle radiosensitization.","journal-title":"Nanoscale"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clon.2013.06.011","volume":"25","author":"Coulter J.A.","year":"2013","unstructured":"Coulter JA, Hyland WB, Nicol J, Currell FJ. Radiosensitising nanoparticles as novel cancer therapeutics--pipe dream or realistic prospect?","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fchem.2014.00086","volume":"2","author":"Cooper D.R.","year":"2014","unstructured":"Cooper DR, Bekah D, Nadeau JL. Gold nanoparticles and their alternatives for radiation therapy enhancement.","journal-title":"Front Chem"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3390\/cancers3011081","volume":"3","author":"Jelveh S.","year":"2011","unstructured":"Jelveh S, Chithrani DB. Gold nanostructures as a platform for combinational therapy in future cancer therapeutics.","journal-title":"Cancers (Basel)"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1259\/bjr\/59448833","volume":"85","author":"Jain S.","year":"2012","unstructured":"Jain S, Hirst DG, O\u2019Sullivan JM. Gold nanoparticles as novel agents for cancer therapy.","journal-title":"Br J Radiol"},{"key":"ref=102","first-page":"86","volume":"11","author":"Su X-Y.","year":"2014","unstructured":"Su X-Y, Liu P-D, Wu H, Gu N. Enhancement of radiosensitization by metal-based nanoparticles in cancer radiation therapy.","journal-title":"Cancer Biol Med"},{"key":"ref=103","first-page":"280","volume":"2","author":"Dorsey J.F.","year":"2013","unstructured":"Dorsey JF, Sun L, Joh DY, Witztum A, Kao GD, Alonso-Basanta M, Avery S, Hahn SM, Al Zaki A, Tsourkas A. Gold nanoparticles in radiation research: potential applications for imaging and radiosensitization.","journal-title":"Transl Cancer Res"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"8197","DOI":"10.1016\/j.biomaterials.2014.06.010","volume":"35","author":"Yao M.H.","year":"2014","unstructured":"Yao MH, Ma M, Chen Y, Jia XQ, Xu G, Xu HX, Chen HR, Wu R. Multifunctional Bi2S3\/PLGA nanocapsule for combined HIFU\/radiation therapy.","journal-title":"Biomaterials"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"23047","DOI":"10.1021\/jp306543q","volume":"116","author":"Hossain M.","year":"2012","unstructured":"Hossain M, Su M. Nanoparticle location and material dependent dose enhancement in X-ray radiation therapy.","journal-title":"J Phys Chem C Nanomater Interfaces"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"012025","DOI":"10.1088\/1742-6596\/444\/1\/012025","volume":"444","author":"Alqathami M.","year":"2013","unstructured":"Alqathami M, Blencowe A, Yeo UJ, Franich R, Doran S, Qiao G, Geso M. Enhancement of radiation effects by bismuth oxide nanoparticles for kilovoltage X-ray beams: A dosimetric study using a novel multi-compartment 3D radiochromic dosimeter.","journal-title":"J Phys Conf Ser"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1166\/jbn.2016.2183","volume":"12","author":"Alqathami M.","year":"2016","unstructured":"Alqathami M, Blencowe A, Geso M, Ibbott G. Quantitative 3D determination of radiosensitization by bismuth-based nanoparticles.","journal-title":"J Biomed Nanotechnol"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1039\/C2NR33154C","volume":"5","author":"Luo Y.","year":"2013","unstructured":"Luo Y, Hossain M, Wang C, Qiao Y, An J, Ma L, Su M. Targeted nanoparticles for enhanced X-ray radiation killing of multidrug-resistant bacteria.","journal-title":"Nanoscale"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1002\/adma.201504617","volume":"28","author":"Song G.","year":"2016","unstructured":"Song G, Liang C, Yi X, Zhao Q, Cheng L, Yang K, Liu Z. Perfluorocarbon-loaded hollow Bi2Se3 nanoparticles for timely supply of oxygen under near-infrared light to enhance the radiotherapy of cancer.","journal-title":"Adv Mater"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.biomaterials.2014.10.001","volume":"37","author":"Ma M.","year":"2015","unstructured":"Ma M, Huang Y, Chen H, Jia X, Wang S, Wang Z, Shi J. Bi2S3-embedded mesoporous silica nanoparticles for efficient drug delivery and interstitial radiotherapy sensitization.","journal-title":"Biomaterials"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"24412","DOI":"10.1039\/c4ra02160f","volume":"4","author":"Bogusz K.","year":"2014","unstructured":"Bogusz K, Tehei M, Stewart C, McDonald M, Cardillo D, Lerch M, Corde S, Rosenfeld A, Liu HK, Konstantinov K. Synthesis of potential theranostic system consisting of methotrexate-immobilized (3-aminopropyl)trimethoxysilane coated \u03b1-Bi2O3 nanoparticles for cancer treatment.","journal-title":"RSC Advances"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0169-409X(98)00105-7","volume":"37","author":"Krause W.","year":"1999","unstructured":"Krause W. Delivery of diagnostic agents in computed tomography.","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1021\/cr980441p","volume":"99","author":"Yu S.B.","year":"1999","unstructured":"Yu SB, Watson AD. Metal-based X-ray contrast media.","journal-title":"Chem Rev"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-3-540-72718-7_8","volume":"185","author":"Speck U.","year":"2008","unstructured":"Speck U. Contrast agents: X-ray contrast agents and molecular imaging - a contradiction?.","journal-title":"Handb Exp Pharmacol"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"12308","DOI":"10.1002\/anie.201104507","volume":"50","author":"Kinsella J.M.","year":"2011","unstructured":"Kinsella JM, Jimenez RE, Karmali PP, Rush AM, Kotamraju VR, Gianneschi NC, Ruoslahti E, Stupack D, Sailor MJ. X-ray computed tomography imaging of breast cancer by using targeted peptide-labeled bismuth sulfide nanoparticles.","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"9635","DOI":"10.1002\/anie.201005657","volume":"49","author":"Pan D.","year":"2010","unstructured":"Pan D, Roessl E, Schlomka JP, Caruthers SD, Senpan A, Scott MJ, Allen JS, Zhang H, Hu G, Gaffney PJ, Choi ET, Rasche V, Wickline SA, Proksa R, Lanza GM. Computed tomography in color: NanoK-enhanced spectral CT molecular imaging.","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1016\/j.materresbull.2013.05.091","volume":"48","author":"Huang H-H.","year":"2013","unstructured":"Huang H-H, Chen J, Meng Y-Z, Yang X-Q, Zhang M-Z, Yu Y, Ma Z-Y, Zhao Y-D. Synthesis and characterization of Bi2S3 composite nanoparticles with high X-ray absorption.","journal-title":"Mater Res Bull"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1039\/c3tb20742k","volume":"1","author":"Rivera E.J.","year":"2013","unstructured":"Rivera EJ, Tran LA, Hern\u00e1ndez-Rivera M, Yoon D, Mikos AG, Rusakova IA, Cheong BY, Cabreira-Hansen MD, Willerson JT, Perin EC, Wilson LJ. Bismuth@US-tubes as a potential contrast agent for X-ray imaging applications.","journal-title":"J Mater Chem B Mater Biol Med"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1002\/adma.201103289","volume":"23","author":"Ai K.","year":"2011","unstructured":"Ai K, Liu Y, Liu J, Yuan Q, He Y, Lu L. Large-scale synthesis of Bi(2)S(3) nanodots as a contrast agent for in vivo X-ray computed tomography imaging.","journal-title":"Adv Mater"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1464-410X.2006.06523.x","volume":"99","author":"Acher P.L.","year":"2007","unstructured":"Acher PL, Hodgson DJ, Murphy DG, Cahill DJ. High-intensity focused ultrasound for treating prostate cancer.","journal-title":"BJU Int"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1158\/0008-5472.CAN-06-3569","volume":"67","author":"Friesen C.","year":"2007","unstructured":"Friesen C, Glatting G, Koop B, Schwarz K, Morgenstern A, Apostolidis C, Debatin KM, Reske SN. Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells.","journal-title":"Cancer Res"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood.V100.4.1233.h81602001233_1233_1239","volume":"100","author":"Jurcic J.G.","year":"2002","unstructured":"Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud AM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA. Targeted \u03b1 particle immunotherapy for myeloid leukemia.","journal-title":"Blood"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1158\/1078-0432.CCR-10-0382","volume":"16","author":"Rosenblat T.L.","year":"2010","unstructured":"Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG. Sequential cytarabine and \u03b1-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.","journal-title":"Clin Cancer Res"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ejca.2013.04.008","volume":"49","author":"Friesen C.","year":"2013","unstructured":"Friesen C, Roscher M, Hormann I, Leib O, Marx S, Moreno J, Miltner E. Anti-CD33-antibodies labelled with the alpha-emitter Bismuth-213 kill CD33-positive acute myeloid leukaemia cells specifically by activation of caspases and break radio- and chemoresistance by inhibition of the anti-apoptotic proteins X-linked inhibitor of apoptosis protein and B-cell lymphoma-extra large.","journal-title":"Eur J Cancer"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2967\/jnumed.112.111997","volume":"54","author":"Ch\u00e9rel M.","year":"2013","unstructured":"Ch\u00e9rel M, Gouard S, Gaschet J, Sa\u00ef-Maurel C, Bruchertseifer F, Morgenstern A, Bourgeois M, Gestin J-F, Bod\u00e9r\u00e9 FK, Barbet J, Moreau P, Davodeau F. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma.","journal-title":"J Nucl Med"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.18632\/oncotarget.2986","volume":"6","author":"Teiluf K.","year":"2015","unstructured":"Teiluf K, Seidl C, Blechert B, Gaertner FC, Gilbertz K-P, Fernandez V, Bassermann F, Endell J, Boxhammer R, Leclair S, Vallon M, Aichler M, Feuchtinger A, Bruchertseifer F, Morgenstern A, Essler M. \u03b1-Radioimmunotherapy with Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.","journal-title":"Oncotarget"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.nucmedbio.2014.02.008","volume":"41","author":"Gouard S.","year":"2014","unstructured":"Gouard S, Pallardy A, Gaschet J, Faivre-Chauvet A, Bruchertseifer F, Morgenstern A, Maurel C, Matous E, Kraeber-Bod\u00e9r\u00e9 F, Davodeau F, Ch\u00e9rel M. Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy.","journal-title":"Nucl Med Biol"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.4161\/cbt.4.12.2251","volume":"4","author":"Allen B.J.","year":"2005","unstructured":"Allen BJ, Raja C, Rizvi S, Li Y, Tsui W, Graham P, Thompson JF, Reisfeld RA, Kearsley J, Morgenstern A, Apostolidis C. Intralesional targeted alpha therapy for metastatic melanoma.","journal-title":"Cancer Biol Ther"},{"key":"ref=129","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4161\/cbt.6.6.4089","volume":"6","author":"Raja C.","year":"2007","unstructured":"Raja C, Graham P, Abbas Rizvi SM, Song E, Goldsmith H, Thompson J, Bosserhoff A, Morgenstern A, Apostolidis C, Kearsley J, Reisfeld R, Allen BJ. Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma.","journal-title":"Cancer Biol Ther"},{"key":"ref=130","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1158\/1078-0432.CCR-05-2820","volume":"12","author":"Kneifel S.","year":"2006","unstructured":"Kneifel S, Cordier D, Good S, Ionescu MCS, Ghaffari A, Hofer S, Kretzschmar M, Tolnay M, Apostolidis C, Waser B, Arnold M, Mueller-Brand J, Maecke HR, Reubi JC, Merlo A. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p.","journal-title":"Clin Cancer Res"},{"key":"ref=131","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00259-010-1385-5","volume":"37","author":"Cordier D.","year":"2010","unstructured":"Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S, M\u00fcller-Brand J, M\u00e4cke H, Reubi JC, Merlo A. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=132","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.nucmedbio.2011.07.003","volume":"39","author":"Gustafsson A.M.E.","year":"2012","unstructured":"Gustafsson AME, B\u00e4ck T, Elgqvist J, Jacobsson L, Hultborn R, Albertsson P, Morgenstern A, Bruchertseifer F, Jensen H, Lindegren S. Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model.","journal-title":"Nucl Med Biol"},{"key":"ref=133","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1158\/0008-5472.CAN-07-6308","volume":"68","author":"Song H.","year":"2008","unstructured":"Song H, Shahverdi K, Huso DL, Esaias C, Fox J, Liedy A, Zhang Z, Reilly RT, Apostolidis C, Morgenstern A, Sgouros G. 213Bi (\u03b1-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model.","journal-title":"Cancer Res"},{"key":"ref=134","doi-asserted-by":"crossref","first-page":"8941","DOI":"10.1158\/0008-5472.CAN-09-1828","volume":"69","author":"Song H.","year":"2009","unstructured":"Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, Apostolidis C, Morgenstern A, Sgouros G. Radioimmunotherapy of breast cancer metastases with \u03b1-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.","journal-title":"Cancer Res"},{"key":"ref=135","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1463-1318.2001.00264.x","volume":"3","author":"Rizvi S.M.A.","year":"2001","unstructured":"Rizvi SMA, Allen BJ, Tian Z, Goozee G, Sarkar S. In vitro and preclinical studies of targeted alpha therapy (TAT) for colorectal cancer.","journal-title":"Colorectal Dis"},{"key":"ref=136","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.ijrobp.2004.04.035","volume":"60","author":"Li Y.","year":"2004","unstructured":"Li Y, Abbas Rizvi SM. Blair nee Brown, J.M.; Cozzi, P.J.; Qu, C.F.; Ow, K.T.; Tam, P.N.; Perkins, A.C.; Russell, P.J.; Allen, B.J. Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted \u03b1-therapy with 213Bi-conjugates.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=137","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.canlet.2003.10.035","volume":"205","author":"Li Y.","year":"2004","unstructured":"Li Y, Cozzi PJ, Qu CF, Zhang DY, Abbas Rizvi SM, Raja C, Allen BJ. Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin \u03b1-conjugate.","journal-title":"Cancer Lett"},{"key":"ref=138","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10585-005-5788-9","volume":"22","author":"Qu C.F.","year":"2005","unstructured":"Qu CF, Song EY, Li Y, Rizvi SMA, Raja C, Smith R, Morgenstern A, Apostolidis C, Allen BJ. Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer.","journal-title":"Clin Exp Metastasis"},{"key":"ref=139","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2217\/imt.14.16","volume":"6","author":"Seidl C.","year":"2014","unstructured":"Seidl C. Radioimmunotherapy with \u03b1-particle-emitting radionuclides.","journal-title":"Immunotherapy"},{"key":"ref=140","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2174\/1874471011104040295","volume":"4","author":"Morgenstern A.","year":"2011","unstructured":"Morgenstern A, Bruchertseifer F, Apostolidis C. Targeted alpha therapy with 213Bi.","journal-title":"Curr Radiopharm"},{"key":"ref=141","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1039\/c3cc41554f","volume":"49","author":"Ramogida C.F.","year":"2013","unstructured":"Ramogida CF, Orvig C. Tumour targeting with radiometals for diagnosis and therapy.","journal-title":"Chem Commun (Camb)"},{"key":"ref=142","first-page":"67","volume":"3","author":"Allen B.","year":"2013","unstructured":"Allen B. Systemic targeted alpha radiotherapy for cancer.","journal-title":"J Biomed Phys Eng"},{"key":"ref=143","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1039\/b704726f","volume":"43","author":"Brechbiel M.W.","year":"2007","unstructured":"Brechbiel MW. Targeted \u03b1-therapy: past, present, future?","journal-title":"Dalton Trans"},{"key":"ref=144","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00259-005-1803-2","volume":"32","author":"Couturier O.","year":"2005","unstructured":"Couturier O, Supiot S, Degraef-Mougin M, Faivre-Chauvet A, Carlier T, Chatal JF, Davodeau F, Cherel M. Cancer radioimmunotherapy with alpha-emitting nuclides.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=145","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s13277-011-0286-y","volume":"33","author":"Kim Y.S.","year":"2012","unstructured":"Kim YS, Brechbiel MW. An overview of targeted alpha therapy.","journal-title":"Tumour Biol"},{"key":"ref=146","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1158\/0008-5472.CAN-10-1186","volume":"71","author":"Wild D.","year":"2011","unstructured":"Wild D, Frischknecht M, Zhang H, Morgenstern A, Bruchertseifer F, Boisclair J, Provencher-Bolliger A, Reubi JC, Maecke HR. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).","journal-title":"Cancer Res"},{"key":"ref=147","doi-asserted-by":"crossref","first-page":"e64730","DOI":"10.1371\/journal.pone.0064730","volume":"8","author":"Wulbrand C.","year":"2013","unstructured":"Wulbrand C, Seidl C, Gaertner FC, Bruchertseifer F, Morgenstern A, Essler M, Senekowitsch-Schmidtke R. Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation.","journal-title":"PLoS One"},{"key":"ref=148","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.nucmedbio.2006.03.004","volume":"33","author":"Chong H-S.","year":"2006","unstructured":"Chong H-S, Milenic DE, Garmestani K, Brady ED, Arora H, Pfiester C, Brechbiel MW. In vitro and in vivo evaluation of novel ligands for radioimmunotherapy.","journal-title":"Nucl Med Biol"},{"key":"ref=149","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/0008-5472.CAN-09-4548","volume":"70","author":"Lingappa M.","year":"2010","unstructured":"Lingappa M, Song H, Thompson S, Bruchertseifer F, Morgenstern A, Sgouros G. Immunoliposomal delivery of 213Bi for \u03b1-emitter targeting of metastatic breast cancer.","journal-title":"Cancer Res"},{"key":"ref=150","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.nucmedbio.2007.04.001","volume":"34","author":"Boswell C.A.","year":"2007","unstructured":"Boswell CA, Brechbiel MW. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.","journal-title":"Nucl Med Biol"},{"key":"ref=151","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1089\/cbr.2013.1531","volume":"29","author":"Meredith R.F.","year":"2014","unstructured":"Meredith RF, Torgue J, Azure MT, Shen S, Saddekni S, Banaga E, Carlise R, Bunch P, Yoder D, Alvarez R. Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.","journal-title":"Cancer Biother Radiopharm"},{"key":"ref=152","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1118\/1.4923843","volume":"42","author":"Shen E.B.S.","year":"2015","unstructured":"Shen EBS, Meredith R, Azure M, Yoder D. Torgue, J. Imaging 212Pb-TCMC-Trastuzumab for alpha radioimmunotherapy for ovarian cancer.","journal-title":"Med Phys"},{"key":"ref=153","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0031-6997(24)01426-1","volume":"51","author":"Drummond D.C.","year":"1999","unstructured":"Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.","journal-title":"Pharmacol Rev"},{"key":"ref=154","first-page":"1639","volume":"36","author":"Boerman O.C.","year":"1995","unstructured":"Boerman OC, Storm G, Oyen WJ, van Bloois L, van der Meer JW, Claessens RA, Crommelin DJ, Corstens FH. Sterically stabilized liposomes labeled with indium-111 to image focal infection.","journal-title":"J Nucl Med"},{"key":"ref=155","first-page":"39","volume":"8","author":"Kontermann R.E.","year":"2006","unstructured":"Kontermann RE. Immunoliposomes for cancer therapy.","journal-title":"Curr Opin Mol Ther"},{"key":"ref=156","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1021\/bc070075t","volume":"18","author":"Sofou S.","year":"2007","unstructured":"Sofou S, Kappel BJ, Jaggi JS, McDevitt MR, Scheinberg DA, Sgouros G. Enhanced retention of the \u03b1-particle-emitting daughters of Actinium-225 by liposome carriers.","journal-title":"Bioconjug Chem"},{"key":"ref=157","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1039\/C3CS60304K","volume":"43","author":"Price E.W.","year":"2014","unstructured":"Price EW, Orvig C. Matching chelators to radiometals for radiopharmaceuticals.","journal-title":"Chem Soc Rev"},{"key":"ref=158","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0039-9140(93)80004-B","volume":"40","author":"Kragten J.","year":"1993","unstructured":"Kragten J, Decnop-Weever LG, Gr\u00fcndler P. Mixed hydroxide complex formation and solubility of bismuth in nitrate and perchlorate medium.","journal-title":"Talanta"},{"key":"ref=159","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0003-2670(95)00467-X","volume":"319","author":"Cukrowski I.","year":"1996","unstructured":"Cukrowski I, Hancock RD, Luckay RC. Formation constant calculation for non-labile complexes based on a labile part of the metal-ligand system. A differential pulse polarographic study at fixed ligand to metal ratio and varied pH: Application to polarographically inactive complexes.","journal-title":"Anal Chim Acta"},{"key":"ref=160","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1016\/j.ccr.2006.02.032","volume":"250","author":"Stavila V.","year":"2006","unstructured":"Stavila V, Davidovich RL, Gulea A, Whitmire KH. Bismuth(III) complexes with aminopolycarboxylate and polyaminopolycarboxylate ligands: Chemistry and structure.","journal-title":"Coord Chem Rev"},{"key":"ref=161","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.semnuclmed.2003.11.002","volume":"34","author":"Borghaei H.","year":"2004","unstructured":"Borghaei H, Schilder RJ. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).","journal-title":"Semin Nucl Med"},{"key":"ref=162","first-page":"141S","volume":"46","author":"Jhanwar Y.S.","year":"2005","unstructured":"Jhanwar YS, Divgi C. Current status of therapy of solid tumors.","journal-title":"J Nucl Med"},{"key":"ref=163","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1021\/cr000118y","volume":"101","author":"Hassfjell S.","year":"2001","unstructured":"Hassfjell S, Brechbiel MW. The development of the \u03b1-particle emitting radionuclides 212Bi and 213Bi, and their decay chain related radionuclides, for therapeutic applications.","journal-title":"Chem Rev"},{"key":"ref=164","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1039\/C39890000145","volume":"3","author":"Kumar K.","year":"1989","unstructured":"Kumar K, Magerstadt M, Gansow OA. Lead(II) and bismuth(III) complexes of the polyazacycloalkene-N-acetic acids NOTA, DOTA, and TETA.","journal-title":"J Chem Soc Chem Commun"},{"key":"ref=165","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1021\/ic00006a021","volume":"30","author":"Kodama M.","year":"1991","unstructured":"Kodama M, Koike T, Mahatma AB, Kimura E. Thermodynamic and kinetic studies of lanthanide complexes of 1,4,7,10,13-pentaazacyclopentadecane-N,N\u2032,N\u2032',N\u201c',N\u2018\u201c'-pentaacetic acid and 1,4,7,10,13,16-hexaazacyclooctadecane-N,N\u2032,N\u201d,N\u2019\u201d,N\u2032\u201d',N\u2032\u201d\u201d-hexaacetic acid.","journal-title":"Inorg Chem"},{"key":"ref=166","doi-asserted-by":"crossref","first-page":"6343","DOI":"10.1021\/ic951326p","volume":"35","author":"Brechbiel M.W.","year":"1996","unstructured":"Brechbiel MW, Gansow OA, Pippin CG, Rogers RD, Planalp RP. Preparation of the novel chelating agent N-(2-aminoethyl)-trans-1,2-diaminocyclohexane-N,N\u2032,N\u201d-pentaacetic acid (H5CyDTPA), a preorganized analogue of diethylenetriaminepentaacetic acid (H5DTPA), and the structure of BiIII(CyDTPA)2\u2013 and BiIII(H2DTPA) complexes.","journal-title":"Inorg Chem"},{"key":"ref=167","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0040-6031(92)80052-X","volume":"195","author":"Rojo T.","year":"1992","unstructured":"Rojo T, Insausti M, Arriortua MI, Hernandez E. Thermal decomposition study of some complexes, precursors of mixed oxides, with formula MM\u2019(L)\u00b7nH2O (M, M\u2032 = Bi, Pb, Sr, Ca and Cu; L = EDTA-like ligands).","journal-title":"Thermochim Acta"},{"key":"ref=168","first-page":"446","volume":"31","author":"Gdaniec M.","year":"2005","unstructured":"Gdaniec M, Simonov Y A. Synthesis and structure of heterometallic Bi(III) complex with diethylenetriaminepentaacetic acid."},{"key":"ref=169","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1021\/ic0261272","volume":"42","author":"Csajb\u00f3k E.","year":"2003","unstructured":"Csajb\u00f3k E, Baranyai Z, B\u00e1nyai I, Br\u00fccher E, Kir\u00e1ly R, M\u00fcller-Fahrnow A, Platzek J, Rad\u00fcchel B, Sch\u00e4fer M. Equilibrium, 1H and 13C NMR spectroscopy, and X-ray diffraction studies on the complexes Bi(DOTA)- and Bi(DO3A-Bu).","journal-title":"Inorg Chem"},{"key":"ref=170","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.nucmedbio.2013.01.012","volume":"40","author":"Kang C.S.","year":"2013","unstructured":"Kang CS, Song HA, Milenic DE, Baidoo KE, Brechbiel MW, Chong HS. Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: radiolabeling, serum stability, and biodistribution and tumor uptake studies.","journal-title":"Nucl Med Biol"},{"key":"ref=171","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1021\/bc800050x","volume":"19","author":"Chong H.S.","year":"2008","unstructured":"Chong HS, Song HA, Ma X, Milenic DE, Brady ED, Lim S, Lee H, Baidoo K, Cheng D, Brechbiel MW. Novel bimodal bifunctional ligands for radioimmunotherapy and targeted MRI.","journal-title":"Bioconjug Chem"},{"key":"ref=172","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1039\/c0cc05707j","volume":"47","author":"Chong H-S.","year":"2011","unstructured":"Chong H-S, Song HA, Kang CS, Le T, Sun X, Dadwal M, Lee H, Lan X, Chen Y, Dai A. A highly effective bifunctional ligand for radioimmunotherapy applications.","journal-title":"Chem Commun (Camb)"},{"key":"ref=173","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1016\/j.bmcl.2008.03.084","volume":"18","author":"Chong H.S.","year":"2008","unstructured":"Chong HS, Song HA, Birch N, Le T, Lim S, Ma X. Efficient synthesis and evaluation of bimodal ligand NETA.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=174","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1021\/jm070401q","volume":"51","author":"Chong H.S.","year":"2008","unstructured":"Chong HS, Ma X, Le T, Kwamena B, Milenic DE, Brady ED, Song HA, Brechbiel MW. Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapy.","journal-title":"J Med Chem"},{"key":"ref=175","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1016\/j.bmcl.2008.09.063","volume":"18","author":"Chong H.S.","year":"2008","unstructured":"Chong HS, Lim S, Baidoo KE, Milenic DE, Ma X, Jia F, Song HA, Brechbiel MW, Lewis MR. Synthesis and biological evaluation of a novel decadentate ligand DEPA.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=176","doi-asserted-by":"crossref","first-page":"7513","DOI":"10.1016\/j.bmcl.2011.06.107","volume":"21","author":"Dadwal M.","year":"2011","unstructured":"Dadwal M, Kang CS, Song HA, Sun X, Dai A, Baidoo KE, Brechbiel MW, Chong HS. Synthesis and evaluation of a bifunctional chelate for development of Bi(III)-labeled radioimmunoconjugates.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=177","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1021\/bc100586y","volume":"22","author":"Song H.A.","year":"2011","unstructured":"Song HA, Kang CS, Baidoo KE, Milenic DE, Chen Y, Dai A, Brechbiel MW, Chong HS. Efficient bifunctional decadentate ligand 3p-C-DEPA for targeted \u03b1-radioimmunotherapy applications.","journal-title":"Bioconjug Chem"},{"key":"ref=178","doi-asserted-by":"crossref","first-page":"8615","DOI":"10.1039\/c2dt30230f","volume":"41","author":"Montavon G.","year":"2012","unstructured":"Montavon G, Le Du A, Champion J, Rabung T, Morgenstern A. DTPA complexation of bismuth in human blood serum.","journal-title":"Dalton Trans"},{"key":"ref=179","first-page":"882","volume":"35","author":"Camera L.","year":"1994","unstructured":"Camera L, Kinuya S, Garmestani K, Wu C, Brechbiel MW, Pai LH, McMurry TJ, Gansow OA, Pastan I, Paik CH. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies.","journal-title":"J Nucl Med"},{"key":"ref=180","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1021\/bc000145v","volume":"12","author":"Liu S.","year":"2001","unstructured":"Liu S, Edwards DS. Stabilization of (90)y-labeled DOTA-biomolecule conjugates using gentisic acid and ascorbic acid.","journal-title":"Bioconjug Chem"},{"key":"ref=181","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.nucmedbio.2014.12.007","volume":"42","author":"Wilson J.J.","year":"2015","unstructured":"Wilson JJ, Ferrier M, Radchenko V, Maassen JR, Engle JW, Batista ER, Martin RL, Nortier FM, Fassbender ME, John KD, Birnbaum ER. Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes.","journal-title":"Nucl Med Biol"},{"key":"ref=182","doi-asserted-by":"crossref","first-page":"12371","DOI":"10.1039\/C4CC05529B","volume":"50","author":"Lima L.M.P.","year":"2014","unstructured":"Lima LMP, Beyler M, Oukhatar F, Le Saec P, Faivre-Chauvet A, Platas-Iglesias C, Delgado R, Tripier RH. Me-do2pa: an attractive chelator with fast, stable and inert (nat)Bi and Bi complexation for potential \u03b1-radioimmunotherapy applications.","journal-title":"Chem Commun (Camb)"},{"key":"ref=183","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.ica.2008.08.013","volume":"362","author":"Morfin J.F.","year":"2009","unstructured":"Morfin JF, Tripier R, Le Baccon M, Handel H. Bismuth(III) complexes with tetra-pyridylmethyl-cyclen.","journal-title":"Inorg Chim Acta"},{"key":"ref=184","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1016\/j.poly.2009.08.003","volume":"28","author":"Morfin J.F.","year":"2009","unstructured":"Morfin JF, Tripier R, Le Baccon M, Handel H. Bismuth(III) coordination to cyclen and cyclam bearing four appended groups.","journal-title":"Polyhedron"},{"key":"ref=185","doi-asserted-by":"crossref","first-page":"13419","DOI":"10.1021\/ic302322r","volume":"51","author":"Rodr\u00edguez-Rodr\u00edguez A.","year":"2012","unstructured":"Rodr\u00edguez-Rodr\u00edguez A, Esteban-G\u00f3mez D, de Blas A, Rodr\u00edguez-Blas T, Botta M, Tripier R, Platas-Iglesias C. Solution structure of Ln(III) complexes with macrocyclic ligands through theoretical evaluation of 1H NMR contact shifts.","journal-title":"Inorg Chem"},{"key":"ref=186","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1021\/ic202436j","volume":"51","author":"Rodr\u00edguez-Rodr\u00edguez A.","year":"2012","unstructured":"Rodr\u00edguez-Rodr\u00edguez A, Esteban-G\u00f3mez D, de Blas A, Rodr\u00edguez-Blas T, Fekete M, Botta M, Tripier R, Platas-Iglesias C. Lanthanide(III) complexes with ligands derived from a cyclen framework containing pyridinecarboxylate pendants. The effect of steric hindrance on the hydration number.","journal-title":"Inorg Chem"},{"key":"ref=187","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.apradiso.2012.07.014","volume":"70","author":"Pomm\u00e9 S.","year":"2012","unstructured":"Pomm\u00e9 S, Marouli M, Suliman G, Dikmen H, Van Ammel R, Jobb\u00e1gy V, Dirican A, Stroh H, Paepen J, Bruchertseifer F, Apostolidis C, Morgenstern A. Measurement of the 225Ac half-life.","journal-title":"Appl Radiat Isot"},{"key":"ref=188","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1126\/science.1064126","volume":"294","author":"McDevitt M.R.","year":"2001","unstructured":"McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, Wu K, Pellegrini V, Curcio MJ, Miederer M, Bander NH, Scheinberg DA. Tumor therapy with targeted atomic nanogenerators.","journal-title":"Science"},{"key":"ref=189","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/ph8020321","volume":"8","author":"de Kruijff R.M.","year":"2015","unstructured":"de Kruijff RM, Wolterbeek HT, Denkova AG. A critical review of alpha radionuclide therapy - how to deal with recoiling daughters?","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=190","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1158\/0008-5472.CAN-04-3096","volume":"65","author":"Jaggi J.S.","year":"2005","unstructured":"Jaggi JS, Kappel BJ, McDevitt MR, Sgouros G, Flombaum CD, Cabassa C, Scheinberg DA. Efforts to control the errant products of a targeted in vivo generator.","journal-title":"Cancer Res"},{"key":"ref=191","doi-asserted-by":"crossref","first-page":"e54531","DOI":"10.1371\/journal.pone.0054531","volume":"8","author":"McLaughlin M.F.","year":"2013","unstructured":"McLaughlin MF, Woodward J, Boll RA, Wall JS, Rondinone AJ, Kennel SJ, Mirzadeh S, Robertson JD. Gold coated lanthanide phosphate nanoparticles for targeted alpha generator radiotherapy.","journal-title":"PLoS One"},{"key":"ref=192","first-page":"253","volume":"45","author":"Sofou S.","year":"2004","unstructured":"Sofou S, Thomas JL, Lin HY, McDevitt MR, Scheinberg DA, Sgouros G. Engineered liposomes for potential \u03b1-particle therapy of metastatic cancer.","journal-title":"J Nucl Med"},{"key":"ref=193","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1021\/bc700440a","volume":"19","author":"Chang M.Y.","year":"2008","unstructured":"Chang MY, Seideman J, Sofou S. Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases.","journal-title":"Bioconjug Chem"},{"key":"ref=194","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1524\/ract.2012.1935","volume":"100","author":"Thijssen L.","year":"2012","unstructured":"Thijssen L, Schaart DR, De Vries D, Morgenstern A, Bruchertseifer F, Denkova AG. Polymersomes as nano-carriers to retain harmful recoil nuclides in alpha radionuclide therapy: A feasibility study.","journal-title":"Radiochim Acta"},{"key":"ref=195","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1351\/pac200476071309","volume":"76","author":"Opsteen J.A.","year":"2004","unstructured":"Opsteen JA, Cornelissen JJLM, van Hest JCM. Block copolymer vesicles.","journal-title":"Pure Appl Chem"},{"key":"ref=196","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.apradiso.2013.12.008","volume":"85","author":"Wang G.","year":"2014","unstructured":"Wang G, de Kruijff RM, Rol A, Thijssen L, Mendes E, Morgenstern A, Bruchertseifer F, Stuart MCA, Wolterbeek HT, Denkova AG. Retention studies of recoiling daughter nuclides of 225Ac in polymer vesicles.","journal-title":"Appl Radiat Isot"},{"key":"ref=197","doi-asserted-by":"crossref","first-page":"10942","DOI":"10.1073\/pnas.1731272100","volume":"100","author":"Dadachova E.","year":"2003","unstructured":"Dadachova E, Nakouzi A, Bryan RA, Casadevall A. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=198","first-page":"313","volume":"45","author":"Dadachova E.","year":"2004","unstructured":"Dadachova E, Howell RW, Bryan RA, Frenkel A, Nosanchuk JD, Casadevall A. Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to \u03b3-radiation versus radioimmunotherapy with \u03b1- and \u03b2-emitting radioisotopes.","journal-title":"J Nucl Med"},{"key":"ref=199","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1128\/AAC.00120-06","volume":"50","author":"Martinez L.R.","year":"2006","unstructured":"Martinez LR, Bryan RA, Apostolidis C, Morgenstern A, Casadevall A, Dadachova E. Antibody-guided alpha radiation effectively damages fungal biofilms.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=200","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1086\/503369","volume":"193","author":"Dadachova E.","year":"2006","unstructured":"Dadachova E, Bryan RA, Apostolidis C, Morgenstern A, Zhang T, Moadel T, Torres M, Huang X, Revskaya E, Casadevall A. Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection.","journal-title":"J Infect Dis"},{"key":"ref=201","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1086\/654813","volume":"202","author":"Bryan R.A.","year":"2010","unstructured":"Bryan RA, Jiang Z, Howell RC, Morgenstern A, Bruchertseifer F, Casadevall A, Dadachova E. Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection.","journal-title":"J Infect Dis"},{"key":"ref=202","doi-asserted-by":"crossref","first-page":"830286","DOI":"10.1155\/2011\/830286","volume":"2011","author":"Dadachova E.","year":"2011","unstructured":"Dadachova E, Casadevall A. Cryptococcus neoformans as a model for radioimmunotherapy of infections.","journal-title":"Interdiscip Perspect Infect Dis"},{"key":"ref=203","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11046-011-9476-9","volume":"173","author":"Bryan R.A.","year":"2012","unstructured":"Bryan RA, Guimaraes AJ, Hopcraft S, Jiang Z, Bonilla K, Morgenstern A, Bruchertseifer F, Del Poeta M, Torosantucci A, Cassone A, Nosanchuk JD, Casadevall A, Dadachova E. Toward developing a universal treatment for fungal disease using radioimmunotherapy targeting common fungal antigens.","journal-title":"Mycopathologia"},{"key":"ref=204","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1128\/AAC.00473-11","volume":"56","author":"Jiang Z.","year":"2012","unstructured":"Jiang Z, Bryan RA, Morgenstern A, Bruchertseifer F, Casadevall A, Dadachova E. Treatment of early and established Cryptococcus neoformans infection with radiolabeled antibodies in immunocompetent mice.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=205","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1128\/AAC.01269-08","volume":"53","author":"Rivera J.","year":"2009","unstructured":"Rivera J, Nakouzi AS, Morgenstern A, Bruchertseifer F, Dadachova E, Casadevall A. Radiolabeled antibodies to Bacillus anthracis toxins are bactericidal and partially therapeutic in experimental murine anthrax.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=206","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1128\/AAC.48.5.1624-1629.2004","volume":"48","author":"Dadachova E.","year":"2004","unstructured":"Dadachova E, Burns T, Bryan RA, Apostolidis C, Brechbiel MW, Nosanchuk JD, Casadevall A, Pirofski L. Feasibility of radioimmunotherapy of experimental pneumococcal infection.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=207","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1371\/journal.pmed.0030427","volume":"3","author":"Dadachova E.","year":"2006","unstructured":"Dadachova E, Patel MC, Toussi S, Apostolidis C, Morgenstern A, Brechbiel MW, Gorny MK, Zolla-Pazner S, Casadevall A, Goldstein H. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins.","journal-title":"PLoS Med"},{"key":"ref=208","doi-asserted-by":"crossref","first-page":"e31866","DOI":"10.1371\/journal.pone.0031866","volume":"7","author":"Dadachova E.","year":"2012","unstructured":"Dadachova E, Kitchen SG, Bristol G, Baldwin GC, Revskaya E, Empig C, Thornton GB, Gorny MK, Zolla-Pazner S, Casadevall A. Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication.","journal-title":"PLoS One"},{"key":"ref=209","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1586\/1744666X.2014.908706","volume":"10","author":"Tsukrov D.","year":"2014","unstructured":"Tsukrov D, Dadachova E. The potential of radioimmunotherapy as a new hope for HIV patients.","journal-title":"Expert Rev Clin Immunol"},{"key":"ref=210","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1053\/j.semnuclmed.2008.10.007","volume":"39","author":"Dadachova E.","year":"2009","unstructured":"Dadachova E, Casadevall A. Radioimmunotherapy of infectious diseases.","journal-title":"Semin Nucl Med"},{"key":"ref=211","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fmicb.2011.00283","volume":"2","author":"Nosanchuk J.D.","year":"2012","unstructured":"Nosanchuk JD, Dadachova E. Radioimmunotherapy of fungal diseases: the therapeutic potential of cytocidal radiation delivered by antibody targeting fungal cell surface antigens.","journal-title":"Front Microbiol"},{"key":"ref=212","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/nature03912","volume":"436","author":"Hoffman L.R.","year":"2005","unstructured":"Hoffman LR, D\u2019Argenio DA, MacCoss MJ, Zhang Z, Jones RA, Miller SI. Aminoglycoside antibiotics induce bacterial biofilm formation.","journal-title":"Nature"},{"key":"ref=213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/microbiolspec.AID-0023-2014","volume":"2","author":"Dadachova E.","year":"2014","unstructured":"Dadachova E, Casadevall A. Radiolabeled antibodies for therapy of infectious diseases.","journal-title":"Microbiol Spectr"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/156107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:19:23Z","timestamp":1750897163000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/156107\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":213,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867324666171003113540","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2016-08-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}